NASDAQ:CLRB
Cellectar Biosciences Stock News
$3.98
+0.345 (+9.49%)
At Close: Mar 28, 2024
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
12:27pm, Wednesday, 27'th Mar 2024
Cellectar Biosciences, Inc. (CLRB) Q4 2023 Earnings Call Transcript
Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024
06:40am, Wednesday, 20'th Mar 2024
FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercial
Cellectar Biosciences to Present at the 36th Annual Roth Conference
08:52am, Thursday, 14'th Mar 2024
FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercial
Cellectar Biosciences: A Shoestring Opportunity You're About To Miss
01:34am, Monday, 12'th Feb 2024
Cellectar Biosciences is a developmental biotech focused on a radiolabeled phospholipid for hematologic malignancies, with a focus on Waldenstrom's macroglobulinemia. Their most advanced development i
Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
06:40am, Wednesday, 07'th Feb 2024
FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commerciali
Why Is Cellectar Biosciences (CLRB) Stock Up 16% Today?
08:37am, Monday, 08'th Jan 2024
Cellectar Biosciences (NASDAQ: CLRB ) stock is heading higher on Monday after the company posted positive results from its CLOVER WaM study of iopofosine I 131. According to a press release from the
Cellectar's blood cancer therapy succeeds in trial
06:41am, Monday, 08'th Jan 2024
Cellectar Biosciences said on Monday its therapy iopofosine for Waldenstrom's macroglobulinemia, a type of blood cancer, met the main goal when tested in patients who received at least two prior lines
Cellectar Biosciences to Present at the Targeted Radiopharmaceuticals Summit Europe
08:30am, Tuesday, 05'th Dec 2023
FLORHAM PARK, N.J., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializ
Cellectar Biosciences, Inc. (CLRB) Q3 2023 Earnings Call Transcript
02:19pm, Thursday, 02'nd Nov 2023
Cellectar Biosciences, Inc. (NASDAQ:CLRB ) Q3 2023 Earnings Conference Call November 2, 2023 8:30 AM ET Company Participants Monique Kosse - LifeSci Advisors James Caruso - CEO Chad Kolean - CFO Shane
Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
01:40pm, Thursday, 09'th Mar 2023 GlobeNewswire Inc.
FLORHAM PARK, N.J., March 09, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage biopharmaceutical company focused on the discovery, development and commercialization
Cellectar to Participate at Upcoming Banking Conferences
09:05pm, Wednesday, 08'th Mar 2023 GlobeNewswire Inc.
FLORHAM PARK, N.J., March 08, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and commerci
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical
01:30pm, Wednesday, 15'th Feb 2023 GlobeNewswire Inc.
FLORHAM PARK, N.J., Feb. 15, 2023 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercial
Cellectar Biosciences Announces Shane Lea as Chief Commercial Officer
01:30pm, Wednesday, 30'th Nov 2022 GlobeNewswire Inc.
FLORHAM PARK, N.J., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercial
Cellectar Announces Resolution of Breach of Contract and Intellectual Property Dispute
01:30pm, Wednesday, 16'th Nov 2022 GlobeNewswire Inc.
Secures license to the patents at issue in the lawsuit Secures license to the patents at issue in the lawsuit
Cellectar Biosciences Announces Closing of Concurrent Registered Direct and Private Placement Offerings of Approximately $10.7 Million Priced At-The-Market Under Nasdaq Rules
08:30pm, Tuesday, 25'th Oct 2022 GlobeNewswire Inc.
FLORHAM PARK, N.J., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercial